An Analytical Reference Standard
Cas No.:1165910-22-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LGD-4033 (Ligandrol) is an orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM) that binds to the androgen receptor with a Ki value of 1 nM.1 In animal models,LGD-4033 (Ligandrol) displays robust selectivity for muscle versus prostate tissues, anabolic activity in the muscle, and anti-resorptive and anabolic activity in bone.1 LGD-4033 (Ligandrol) has been abused as a performance-enhancing drug and the identification of its in vitro metabolites has been described.2,3 This product is intended for research and forensic applications.
References:
1.Basaria, S., Collins, L., Dillon, E.L., et al.The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young menJ. Gerontol. A Biol. Sci. Med. Sci.68(1)87-95(2013)
2.Geldof, L., Pozo, O.J., Lootens, L., et al.In vitro metabolism study of a black market product containing SARM LGD-4033Drug Test Anal.9(2)168-178(2016)
3.Thevis, M., Lagojda, A., Kuehne, D., et al.Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the internet and identification of in vitro generated phase-I metabolites for human sports drug testingRapid Commun Mass Spectrom.29(11)991-999(2015)
| Cas No. | 1165910-22-4 | SDF | |
| Canonical SMILES | N#CC1=CC=C(N2[C@@H]([C@@H](O)C(F)(F)F)CCC2)C=C1C(F)(F)F | ||
| 分子式 | C14H12F6N2O | 分子量 | 338.25 |
| 溶解度 | DMSO: ≥ 100 mg/mL (295.64 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9564 mL | 14.782 mL | 29.5639 mL |
| 5 mM | 591.3 μL | 2.9564 mL | 5.9128 mL |
| 10 mM | 295.6 μL | 1.4782 mL | 2.9564 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet